PROMOTE Clinical Trials

Promedior is currently conducting two Phase 2 clinical trials of its product candidate, PRM-151, in patients with Myelofibrosis (MF) and Idiopathic Pulmonary Fibrosis (IPF). PRM-151 is formulated for intravenous injection. Both of these studies have completed enrollment and are no longer recruiting patients.

PRM-151G-101:  A Phase 2, Prospective Study of PRM-151 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)

PRM-151-202:  A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

PROMOTE Clinical Trials